Personalised therapy in follicular lymphoma - is the dial turning?

Kim M Linton*, Lena Specht, Astrid Pavlovsky, Carrie A Thompson, Eva Kimby, Daphne de Jong, Loretta J Nastoupil, Anne-Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun

*Corresponding author af dette arbejde

Abstract

Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.

OriginalsprogEngelsk
TidsskriftHematological Oncology
ISSN0889-8588
DOI
StatusE-pub ahead of print - 22 jul. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Personalised therapy in follicular lymphoma - is the dial turning?'. Sammen danner de et unikt fingeraftryk.

Citationsformater